From: Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
Predicted
Responder
Non-Responder
Indeterminate
Observed
17
1
8
Progressor
0
24
3
Stable Disease
4
6